|

PEP-CMV vaccine Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1/2: 1

Top Sponsors

  • Washington University School of Medicine1

Indications

  • Diffuse Midline High-grade Glioma1
  • Diffuse Midline Glioma1
  • Ependymoma1
  • Medulloblastoma1
  • Cancer1

St Louis, Missouri1 trial

PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma

Washington University School of Medicine

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.